The Holocaust and the racial hygiene doctrine that helped rationalize it still overshadow contemporary debates about using gene editing for disease prevention.
AMA J Ethics. 2021;23(1):E49-54. doi:
10.1001/amajethics.2021.49.
Charles E. Binkley, MD, Michael S. Politz, MA, and Brian P. Green, PhD
If the safe-and-effective standard for judging devices’ potential as therapy or enhancement is inadequate, one might wonder whether BCI regulation should be overseen by the FDA.
AMA J Ethics. 2021;23(9):E745-749. doi:
10.1001/amajethics.2021.745.
Dr Charles Binkley joins Ethics Talk to discuss his article, coauthored with Michael Politz and Dr Brian Green: "Who, If Not the FDA, Should Regulate Implantable Brain-Computer Interface Devices?"
Dr Rajesh R. Tampi joins Ethics Talk to discuss his article, coauthored with Drs Aarti Gupta and Iqbal Ahmed: “Why Does the US Overly Rely on International Medical Graduates in Its Geriatric Psychiatric Workforce?”
Richard A. Yoast, MA, PhD, William J. Filstead, PhD, Bonnie B. Wilford, MS, Susan Hayashi, PhD, Jennifer Reenan, MD, and Jorie Epstein
Curriculum changes can help physicians in training diagnose and treat substance abuse, but there are significant barriers to implementing such changes.
Developing technologies for personalized medicine may be misused to popularize the idea that one can infer a person’s genetic makeup from observer-defined or self-reported assignment to a race or ethnic group.